Lipella Pharmaceuticals (LIPO) shares soared 79% after the company said Thursday it received a US Food and Drug Administration approval for an expanded access program for LP-310, an oral rinse formulation designed to treat oral lichen planus.
Over 82.1 million shares traded intraday versus a daily average of roughly 127,000.
TransCode Therapeutics (RNAZ) said Thursday that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. The dose administered to patients in the cohort was about double that of Cohort 2.
Shares jumped nearly 33% as intraday trading volume climbed to more than 11.7 million from a daily average of over 1.44 million.
Tapestry (TPR) reported Thursday higher fiscal Q2 non-GAAP earnings and net sales while raising its outlook for fiscal 2025.
Shares rose roughly 13%, with intraday trading volume rising to nearly 10.6 million, compared with a daily average of more than 4.87 million.
Price: 4.69, Change: +2.07, Percent Change: +79.05
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。